Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $375
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $320 to $375.
March 15, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson reaffirmed an Outperform rating on Madrigal Pharmaceuticals and increased the price target from $320 to $375.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100